The number of FDA approved antibody-drug conjugates has rapidly risen in the last decade and promises to continue to do so. ADCs are very effective drugs used in the treatment of metastatic diseases and anticancer therapy. Many cancer patients cou...
Antibody drug conjugates (ADCs) are a promising alternative for cancer therapy. Due to the targeting quality of the monoclonal antibody (mAb) in combination with a highly toxic payload drug, it becomes easier to target cancer cells without potenti...
ADCs can be described as a new rising star among biopharmaceutics. They are able to specifically target and destroy cancer cells very effectively. Their levels of toxicity can vary depending on several factors, including their specific design and ...
Bioconjugates have proven to be very useful in the production of therapeutic drugs, diagnostics and research. Bioconjugate manufacturing, therefore, has enabled new advances in biochemistry. In this article, we will explain the basics of bioconjug...
Antibody-drug conjugates (ADCs) are a promising class of targeted cancer therapies that use monoclonal antibodies (mAbs) to selectively deliver potent cytotoxic drugs (cytotoxic agents) to cancer cells. With their ability to reduce systemic toxici...
ADC technology is a promising and exciting new approach in cancer treatment, selectively targeting a specific cell surface receptor expressed on cancer cells. With oncology being a main field of application, a number of preclinical tests for treat...
The safe handling of ADCs or other HPAPIs is a complex and elaborate process that requires specialized facilities and a safe, sterile environment. The filling/aliquoting step in particular calls for great care and specific equipment to ensure ster...
Antibody drug conjugates (ADCs) are a rapidly growing field of interest in biopharmaceutics. In comparison to conventional chemotherapy treatments, ADCs have the potential to destroy cancerous cells without damaging healthy cells in the process. T...
Bioconjugation has become a common method to link small molecular fragments with special properties with much larger and more complex biomolecules like proteins, antibodies, nucleic acids and even cells. The two most important reasons to do this a...
Bioconjugates have been used to develop a range of novel therapeutics, including antibody-drug conjugates (ADCs), which have shown great potential in cancer therapy. The manufacturing of bioconjugates is a complex process that involves linking a d...
Antibody drug conjugates (ADCs) are a class of therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Since the first ADCs entered clinical trials in the 1990s, they have shown great promise in trea...
The Antibody-Drug Conjugate market is poised for strong growth rates in the next five years, with CAGR projections in the double-digits, reaching over ten billion USD. "ADC companies" like Pfizer Inc, Genentech, Gilead Sciences and numerous other...
